Oral delivery of salmon calcitonin

Advanced Drug Delivery Reviews

Volumn 42, Issue 3, 2000, Pages 225-238

  Lee, Yong Hee ^a   Sinko, Patrick J ^a  

^a RUTGERS UNIVERSITY   (United States)

Author keywords

Bioavailability; Oral absorption; Permeability; Salmon calcitonin

Indexed keywords

BONE; DRUG DOSAGE; DRUG PRODUCTS;

BIOAVAILABILITY; SALMON CALCITONIN;

CONTROLLED DRUG DELIVERY;

SALCATONIN;

BIOAVAILABILITY; BONE REMODELING; CALCIUM METABOLISM; DRUG ABSORPTION; DRUG DELIVERY SYSTEM; DRUG FORMULATION; ENZYME SPECIFICITY; HUMAN; INTESTINE ABSORPTION; INTESTINE MUCOSA; MEMBRANE PERMEABILITY; PRIORITY JOURNAL; PROTEIN DEGRADATION; REVIEW;

EID: 0034739238     PISSN: 0169409X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-409X(00)00063-6     Document Type: Article

References (58)

1. McDermott M.T., Kidd G.S. The role of calcitonin in the development and treatment of osteoporosis. Endocr. Rev. 8:1987;377-390.
2. Patel S., Lyons A.R., Hosking D.J. Drugs used in the treatment of metabolic bone diseases. Drugs. 46:1993;594-617.
3. Stevenson J.C., Evans I.M. Pharmacology and therapeutic use of calcitonin. Drugs. 21:1981;257-272.
4. Reginster J.Y., Jeugmans-Huynen A.M., Sarlet N., McIntyre H.D., Franchimont P. The effect of nasal hCT on bone turnover in Paget's disease of bone-implications for the treatment of other metabolic bone diseases. Br. J. Rheumatol. 31:1992;35-39.
5. Schneyer C.R. Calcitonin and the treatment of osteoporosis. Md. Med. J. 40:1991;469-473.
6. Sinko P.J., Hu P., Wagner E., Sturmer A., Gilligan J.P., Stern W. Determination of the intestinal permeability of recombinant salmon calcitonin. Pharm. Res. 10:(Suppl.):1993;S293.
7. Yu H., Jiang F., Stern W., Sinko P.J. Intestinal binding and degradation of recombinant salmon calcitonin. Pharm. Res. 11:(Suppl.):1994;S254.
8. Heintz M.L., Flanigan E., Orlowski R.C., Regnier F.E. Correlation of calcitonin structure with chromatographic retention in high-performance liquid chromatography. J. Chromatogr. 443:1988;229-245.
9. Singer F., Habener J.F., Greene E., Godin P., Pottisjun J.T. Inactivation of calcitonin by specific organs. Nat. New Biol. 237:1972;269-270.
10. Zhou X.H. Overcoming enzymatic and absorption barriers to non-parenterally administered protein and peptide drugs. J. Control. Release. 29:1994;239-252.
11. Amidon G.L., Lee H.J. Absorption of peptide and peptidomimetic drugs. Annu. Rev. Pharmacol. Toxicol. 34:1994;321-341.
12. Lagguth P., Bohner V., Heizmann J., Merckle H.P., Wolffram S., Amidon G.L., Yamashita S. The challenge of proteolytic enzymes in intestinal peptide delivery. J. Control. Release. 46:1997;39-57.
13. Lee V.H.L., Yamamoto A. Penetration and enzymatic barriers to peptide and protein absorption. Adv. Drug Del. Rev. 4:1990;171-207.
14. Bai J.P., Amidon G.L. Structural specificity of mucosal-cell transport and metabolism of peptide drugs: Implications for oral peptide drug delivery. Pharm. Res. 9:1992;969-978.
15. Woodley J.F. Enzymatic barriers for GI peptide and protein delivery. Crit. Rev. Ther. Drug Carrier Syst. 11:1994;61-95.
16. Friedman D.I., Amidon G.L. Oral absorption of peptides: Influence of pH and inhibitors on the intestinal hydrolysis of leu-enkephalin and analogues. Pharm. Res. 8:1991;93-96.
17. Bai J.P., Chang L.L., Guo J.H. Effects of polyacrylic polymers on the luminal proteolysis of peptide drugs in the colon. J. Pharm. Sci. 84:1995;1291-1294.
18. Bai J.P., Chang L.L., Guo J.H. Effects of polyacrylic polymers on the degradation of insulin and peptide drugs by chymotrypsin and trypsin. J. Pharm. Pharmacol. 48:1996;17-21.
19. Grundy D. Gastrointestinal Motility. 1985;MTD Press Limited.
20. Sinko P.J., Smith C.L., McWhorter L.T., Stern W., Wagner E., Gilligan J.P. Utility of Pharmacodynamic measures for assessing the oral bioavailability of peptides. 1. Administration of recombinant salmon calcitonin in rats. J. Pharm. Sci. 84:1995;1374-1378.
21. Y.H. Lee, V. Makhey, H. Yu, P. Hu, B. Perry, J.P. Sutyak, E.J. Wagner, L.M. Falzone, W. Stern, P.J. Sinko, Pharmacokinetics and disposition of salmon calcitonin in beagle dogs, Eur. J. Pharm. Biopharm. (2000) in press.
22. M. Gibaldi, D. Perrier, Pharmacokinetics, 2nd Edition, Marcel Dekker, New York, 1982, pp. 271-318, pp. 409-417.
23. Sinko P.J., Lee Y.H., Makhey V., Leesman G.D., Sutyak J.P., Yu H., Perry B., Smith C.T., Hu P., Wagner E.J., Falzone L.M., McWhorter L.T., Gilligan J.P., Stern W. Biopharmaceutical approaches for developing and assessing oral peptide delivery strategies and systems: In vitro permeability and in vivo oral absorption of salmon calcitonin (sCT). Pharm. Res. 16:1999;527-533.
24. Luise M.D., Martin T.J., Greenberg P.B., Michelangeli V. Metabolism of porcine, human, and salmon calcitonin in the rat. J. Endocr. 53:1972;475-482.
25. Blower P.J., Puncher M.R.B., Kettle A.G., George S., Dorsch S., Leak A., Naylor L.H., O'Doherty M.J. Iodine-123 salmon calcitonin, an imaging agent for calcitonin receptors: synthesis, biodistribution, metabolism, and dosimetry in humans. Eur. J. Nucl. Med. 25:1998;101-108.
26. Birn H., Christensen E.I. Localization and degradation of calcitonin in renal proximal tubule of rat visualized by immunocytochemistry. Ren. Physiol. Biochem. 16:1993;167-181.
27. Moore P.L., Strickland M.L., Crass M.F. Vasoactive characteristics of calcitonin in coronary and hepatic circulations. J. Hypertension. 4:(Suppl. 5):1986;S186-S188.
28. Beglinger C., Born W., Muff R., Drewe J., Dreyfuss J.L., Bock A., Mackay M., Fischer J.A. Intracolonic bioavailability of human calcitonin in man. Eur. J. Clin. Pharmacol. 43:1992;527-531.
29. Antonin K.H., Saano V., Bieck P., Hastewell J., Fox R., Lowe P., Mackay M. Colonic absorption of human calcitonin in man. Clin. Sci. 83:1992;627-631.
30. Wagner E., Gilligan J.P., McWhorter L.T., Burkett-Pazel V., Sinko P.J., Stern W. Rapid detection and identification of salmon calcitonin in plasma after oral or gastrointestinal administration of recombinant salmon calcitonin. Pharm. Res. 11:(Suppl.):1994;S19.
31. Beveridge T., Niederer W., Nuesch E., Petrin A. Pharmacokinetic study with synthetic salmon calcitonin. Z. Gastroenterol. 10:1976;12-15.
32. Huwyler R., Born W., Ohnhaus E.E., Fischer J.A. Plasma kinetics and urinary excretion of exogenous human and salmon calcitonin in man. Am. J. Physiol. 236:1979;E15-E19.
33. Ardaillou R., Paillard F., Sraer J., Vallee G. Compared kinetics of salmon and human radioiodinated calcitonins in man. Horm. Metab. Res. 5:1973;232-233.
34. Nuesch E., Schmidt R. Pecile A. Calcitonin. 1980;352-364 Excerpta Medica, Amsterdam.
35. Hastewell J., Lynch S., Williamson I., Fox R., Mackay M. Absorption of human calcitonin across the rat colon in vivo. Clin. Sci. 82:1992;589-594.
36. Pagani G., Pagani M.D., Gianola D., Pedroncelli A., Cortesi L., Gheradi F., Gualteroni L., Tengattini F., Montini M. Hypocalcemic effects of rectal and intramuscular administration of synthetic salmon calcitonin. Int. J. Clin. Pharmacol. Ther. Toxicol. 29:1991;329-332.
37. Buclin T., Randin J.P., Jacquet A.F., Azira M., Attinger M., Gomez F., Burckhardt P. The effect of rectal and nasal administration of salmon calcitonin in normal subjects. Calcif. Tissue Int. 41:1987;252-258.
38. Saffran M., Kumar G.S., Savariar C., Burnham J.C., Williams F., Neckers D.C. A new approach to the oral administration of insulin and other peptide drugs. Science. 233:1986;1081-1084.
39. Mrsny R.N. The colon as a site for drug delivery. J. Control. Release. 22:1992;15-34.
40. Lee Y.H., Perry B.A., Sutyak J.P., Stern W., Sinko P.J. Regional differences in intestinal spreading and pH recovery on the effectiveness of pharmaceutical excipients and the impact on salmon calcitonin absorption in beagle dogs. Pharm. Res. 17:2000;284-290.
41. Mackay M. Delivery of recombinant peptide and protein drugs. Biotechnol. Genet. Eng. Rev. 8:1991;251-278.
42. Lee Y.H., Perry B.A., Labruno S., Lee H.S., Stern W., Falzone L.M., Sinko P.J. Impact of regional intestinal pH modulation on absorption of peptide drugs: Oral absorption studies of salmon calcitonin in beagle dogs. Pharm. Res. 16:1999;1233-1239.
43. Legg E.F., Spencer A.M. Studies on the stability of pancreatic enzymes in duodenal fluid to storage temperature and pH. Clin. Chim. Acta. 65:1975;175-179.
44. Kagatani S., Shinoda T., Fukui M., Ohmura T., Hasumi S., Sonobe T. Enhancement of nasal calcitonin absorption by lauroylcarnitine chloride in rats. Pharm. Res. 13:1996;739-743.
45. Yamamoto A. Improvement of intestinal absorption of peptide and protein drugs by chemical modification with fatty acids. Nippon Rinsho. 56:1998;601-607.
46. Muranishi S. Delivery system design for improvement of intestinal absorption of peptide drugs. Yakugaku Zassshi. 117:1997;394-414.
47. Leone-Bay A., Santiago N., Achan D., Chaudhary K., DeMorin F., Falzarano L., Haas S., Kalbag S., Kaplan D., Leipold H. N-acylated alpha-amino acids as novel oral delivery agents for proteins. J. Med. Chem. 38:1995;4263-4269.
48. Sakuma S., Sudo R., Suzuki N., Kikuchi H., Akashi M., Hayashi M. Mucoadhesion of polystyrene nanoparticles having surface hydrophilic polymeric chains in the gastrointestinal tract. Int. J. Pharm. 177:1999;161-172.
49. Serres A., Baudys M., Kim S.W. Temperature and pH-sensitive polymers for human calcitonin delivery. Pharm. Res. 13:1996;196-201.
50. Harris A.S. Review: clinical opportunities provided by the nasal administration of peptides. J. Drug Target. 1:1993;101-116.
51. Nakamuta H., Kohno T., Ichikawa M., Hoshino T., Watabe K., Koida M. Plasma level monitoring of nasal salmon calcitonin in the rat by a heterogeneous two-site enzyme immunoassay. J. Clin. Lab. Anal. 11:1997;129-131.
52. Plosker G.L., McTavish D. Intranasal salmon calcitonin. A review of its pharmacological properties and role in the management of postmenopausal osteoporosis. Drugs Aging. 8:1996;378-400.
53. Gennari C., Agnusdei D. Calcitonin and osteoporosis, Br. J. Clin. Pract. 48:1994;196-200.
54. Watanabe Y., Mizufune Y., Utoguchi N., Endo K., Matsumoto M. Studies of drug delivery systems for a therapeutic agent used in osteoporosis. II. Enhanced absorption of elcatonin from nasal mucosa in rabbits. Biol. Pharm. Bull. 21:1998;1191-1194.
55. Kobayashi S., Kondo S., Juni K. Study on pulmonary delivery of salmon calcitonin in rats: effect of protease inhibitors and absorption enhancers. Pharm. Res. 11:1994;1239-1243.
56. Kobayashi S., Kondo S., Juni K. Pulmonary delivery of salmon calcitonin dry powders containing absorption enhancers in rats. Pharm. Res. 13:1996;80-83.
57. Watanabe Y., Mizufune Y., Kubomura A., Kiriyama M., Utoguchi N., Matsumoto M. Studies of drug delivery systems for a therapeutic agent used in osteoporosis. I. Pharmacodynamics (hypocalcemic effect) of elcatonin in rabbits following rectal administration of hollow-type suppositories containing elcatonin. Biol. Pharm. Bull. 21:1998;1187-1190.
58. Sayani A.P., Chien Y.W. Systemic delivery of peptides and proteins across absorptive mucosae. Crit. Rev. Ther. Drug Carrier Syst. 13:1996;85-184.